Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 12/20 | 0.80 |
| ▸ | FNTB | P49356 | 12/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.65 |
| ▸ | PGGT1B | P53609 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5656156 | 0.91 | FNTA (0.68) | FNTAFNTBCYP3A4PGGT1B | |
| Hydrochloric Acid SCHEMBL5658016 | 0.90 | FNTA (0.66) | FNTAFNTBCYP3A4PGGT1B | |
| SCHEMBL6010453 | 0.90 | FNTA (0.68) | FNTAFNTBCYP3A4PGGT1B | |
| Tipifarnib SCHEMBL8097 | 0.89 | FNTA (0.80) | FNTAFNTBCYP3A4PGGT1B | |
| Tipifarnib SCHEMBL22772860 | 0.89 | FNTA (0.80) | FNTAFNTBCYP3A4PGGT1B | |
| Tipifarnib SCHEMBL23633189 | 0.89 | FNTA (0.80) | FNTAFNTBCYP3A4PGGT1B | |
| (S)-Tipifarnib SCHEMBL4429738 | 0.89 | FNTA (0.80) | FNTAFNTBCYP3A4PGGT1B | |
| Tipifarnib SCHEMBL21544535 | 0.89 | FNTA (0.80) | FNTAFNTBCYP3A4PGGT1B | |
| SCHEMBL11947168 | 0.89 | FNTA (1.00) | FNTAFNTBCYP3A4PGGT1B | |
| SCHEMBL6843800 | 0.89 | FNTA (1.00) | FNTAFNTBCYP3A4PGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11542244-B2 | Synthesis of tipifarnib | KURA ONCOLOGY, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-20210246114-A1 | SYNTHESIS OF TIPIFARNIB | KURA ONCOLOGY, INC. (US) | 2021-08-12 | — | — | US | disclosed |
| EP-1756085-B1 | DIASTEREOSELECTIVE SYNTHESIS PROCESS WITH 6-BROMO-4-(3-CHLOROPHENYL)-2-METHOXY-QUINOLINE | JANSSEN PHARMACEUTICA NV (BE) | 2010-06-16 | — | — | EP | disclosed |
| US-7572916-B2 | Diastereoselective synthesis process with 6-bromo-4-(3-chlorophenyl)-2-methoxy-quinoline | JANSSEN PHARMACEUTICA NV (BE) | 2009-08-11 | — | — | US | disclosed |
| US-7572916-B2 | Diastereoselective synthesis process with 6-bromo-4-(3-chlorophenyl)-2-methoxy-quinoline | JANSSEN PHARMACEUTICA NV (BE) | 2009-08-11 | — | — | US | disclosed |
| US-7524961-B2 | Diastereoselective addition of lithiated N-methylimidazole on sulfinimines | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-04-28 | — | — | US | disclosed |
| US-7524961-B2 | Diastereoselective addition of lithiated N-methylimidazole on sulfinimines | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-04-28 | — | — | US | disclosed |
| US-7524961-B2 | Diastereoselective addition of lithiated N-methylimidazole on sulfinimines | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-04-28 | — | — | US | disclosed |
| US-7456287-B2 | Diastereoselective synthesis process for the preparation of imidazole compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-11-25 | — | — | US | disclosed |
| US-7456287-B2 | Diastereoselective synthesis process for the preparation of imidazole compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-11-25 | — | — | US | disclosed |
| US-20070238880-A1 | Diastereoselective Synthesis Process for the Preparation of Imidazole Compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-11 | — | — | US | disclosed |
| US-20070238880-A1 | Diastereoselective Synthesis Process for the Preparation of Imidazole Compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-11 | — | — | US | disclosed |
| US-20070238880-A1 | Diastereoselective Synthesis Process for the Preparation of Imidazole Compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-11 | — | — | US | disclosed |
| EP-1756085-A1 | DIASTEREOSELECTIVE SYNTHESIS PROCESS WITH 6-BROMO-4-(3-CHLOROPHENYL)-2-METHOXY-QUINOLINE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005105783-A1 | DIASTEREOSELECTIVE SYNTHESIS PROCESS WITH 6-BROMO-4-(3-CHLOROPHENYL)-2-METHOXY-QUINOLINE | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-11-10 | — | — | WO | disclosed |
| EP-1373255-B1 | PROCESS FOR THE PREPARATION OF IMIDAZOLE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2005-01-26 | — | — | EP | disclosed |
| US-6844439-B2 | Process for the preparation of imidazole compounds | JANSEN PHARMACEUTICA, NV (BE) | 2005-01-18 | — | — | US | disclosed |
| US-20040138256-A1 | Process for the preparation of imidazole compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-07-15 | — | — | US | disclosed |
| EP-1373255-A1 | PROCESS FOR THE PREPARATION OF IMIDAZOLE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-01-02 | — | — | EP | disclosed |
| WO-2002072574-A1 | PROCESS FOR THE PREPARATION OF IMIDAZOLE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210246114-A1 | SYNTHESIS OF TIPIFARNIB | TIPARP, RTF1, TTBK1 | FNTA 1300/4885FNTB 754/4885CYP3A4 1391/4885 |
| US-20040138256-A1 | Process for the preparation of imidazole compounds | AZI2, DOT1L, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | FNTA 3238/4885FNTB 3264/4885CYP3A4 14/4885 |
| US-11542244-B2 | Synthesis of tipifarnib | TIPARP, RTF1, TTBK1 | FNTA 1300/4885FNTB 754/4885CYP3A4 1391/4885 |
| US-20070238880-A1 | Diastereoselective Synthesis Process for the Preparation of Imidazole Compounds | DHPS, CYP2S1, CYP1A2 | FNTA 1134/4885FNTB 1198/4885CYP3A4 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.